Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 504-510

  Zwaveling, Juliette ^a,b,c   Press, Rogier R ^a   Bredius, Robbert G M ^a   Van Derstraaten, Tahar R J H M ^a   Den Hartigh, Jan ^a   Bartelink, Imke H ^b   Boelens, Jaap Jan ^b   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Department of Clinical Pharmacy and Toxicology ^*  (Netherlands)

Author keywords

Busulfan; GST polypmorphism; Pediatric; Population PK

Indexed keywords

BUSULFAN; BUSULVEX; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; GLUTATHIONE TRANSFERASE; MELPHALAN; UNCLASSIFIED DRUG; ALKYLATING AGENT; DNA;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CHILD; DRUG CLEARANCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; PHARMACOGENETICS; PHARMACOKINETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PYROSEQUENCING; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN OCCLUSION; ADOLESCENT; BIOSYNTHESIS; FEMALE; GENETIC POLYMORPHISM; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER VEIN OBSTRUCTION; MALE; POPULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; DNA; FEMALE; GENETIC VARIATION; GENOTYPE; GLUTATHIONE TRANSFERASE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; POPULATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 53849126189     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181817428     Document Type: Article

References (24)

1. Zwaveling J, den Hartigh J, Lankester AC, et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs. 2006; 17:1099-1105.
2. Booth BP, Rahman A, Dagner RN, et al. Population pharmacokineticbased dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007;47:101-111.
3. Poonkuzhali B, Chandy M, Srivastava A, et al. Glutathione s-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001;29:264-267.
4. Czerwinksi M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu and pi. Drug Metab Dispos. 1996;24:1015-1019.
5. Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics. 2001;11:663-669.
6. Kusama M, Kubota T, Matsukura Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006;368:93-98.
7. Zwaveling J, Bredius RGM, Cremers SCLM, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005;35:17-23.
8. Bearman SI, Appelbaum FR, Back A, et al. Regimen-related toxicity and early posttransplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol. 1989;7:1288-1294.
9. Proost JH, Meijer DKF. PW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22:155-163.
10. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol. 2002;53:368-389.
11. Chow DSL, Bhagwatwar HP, Phadungpojna S, et al. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J Chromatogr B. 1997;704:277-288.
12. Arand M, Muhlbauer R, Hengstler J, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem. 1996;236:184-186.
13. Meibohm B, Laer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7:E475-E487.
14. Hayes JD, Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154-166.
15. Hassan M, Nilsson C, Hassan Z, et al. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m2 as a optimal total dose for conditioning. Bone Marrow Transplant. 2002;30:833-841.
16. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hemotopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease HVOD, HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8: 493-500.
17. Dalle JH, Wall D, Theoret Y, et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant. 2003;32:647-651.
18. Takema H, Tanaka H, Nakashima D, et al. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:345-351.
19. Schechter T, Finkelstein Y, Doyle J, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;3:307-314.
20. Bredschneider M, Klein K, Mürdther TE, et al. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther. 2002;71:479-487.
21. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574-1577.
22. Bertholle-Bonnet V, Bleyzac N, Galambrun C, et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther Drug Monit. 2007;29:177-184.
23. Nakamura H, Sato T, Okada K, et al. Population pharmacokinetics of oral busulfan in young japanese children before hematopoietic stem cell transplantation. Ther Drug Monit. 2008;30:75-83.
24. Gibbs JP, Liacouras CA, Baldassano RN, et al. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos. 1999;27:1466-1469.